139 related articles for article (PubMed ID: 36199992)
1. Urinary toxicity after salvage re-irradiation for prostate cancer local failure after definitive radiotherapy: a clinical and dosimetric prognostic factors analysis.
Dipasquale G; Zilli T; Fiorino C; Achard V; Rouzaud M; Miralbell R
J Contemp Brachytherapy; 2022 Jun; 14(3):222-226. PubMed ID: 36199992
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome.
Ryg U; Seierstad T; Nilsen LB; Hellebust TP; Djupvik LH; Gustafson H; Hydal J; Kishan AU; Hole KH; Lilleby W
Front Oncol; 2022; 12():861127. PubMed ID: 35463376
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
4. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
[TBL] [Abstract][Full Text] [Related]
5. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
[TBL] [Abstract][Full Text] [Related]
6. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control.
Mayrata E; Espinosa JM; Büchser D; Casquero F; Suárez F; González A; Minguez P; Pérez JF; Miguel IS; Cacicedo J; Gómez-Iturriaga A
J Contemp Brachytherapy; 2021 Feb; 13(1):12-17. PubMed ID: 34025731
[TBL] [Abstract][Full Text] [Related]
7. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.
Henríquez I; Sancho G; Hervás A; Guix B; Pera J; Gutierrez C; Abuchaibe O; Martínez-Monge R; Tormo A; Polo A
Radiat Oncol; 2014 Apr; 9():102. PubMed ID: 24885287
[TBL] [Abstract][Full Text] [Related]
8. Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes.
Lewin R; Amit U; Laufer M; Berger R; Dotan Z; Domachevsky L; Davidson T; Portnoy O; Tsvang L; Ben-Ayun M; Weiss I; Symon Z
Radiat Oncol; 2021 Jun; 16(1):114. PubMed ID: 34162398
[TBL] [Abstract][Full Text] [Related]
9. Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of
Sutani S; Yorozu A; Toya K; Nishiyama T; Ozu C; Yagi Y; Nakamura K; Saito S
J Contemp Brachytherapy; 2019 Jun; 11(3):201-206. PubMed ID: 31435426
[TBL] [Abstract][Full Text] [Related]
10. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
11. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
[TBL] [Abstract][Full Text] [Related]
12. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
[TBL] [Abstract][Full Text] [Related]
13. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and dosimetric predictors of toxicity for re-irradiation of vaginal recurrence of endometrial cancer.
Lee LJ; Alban GM; Cheng T; Buzurovic I; Pretz J; Singer L; King MT
Brachytherapy; 2022; 21(3):263-272. PubMed ID: 35078717
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of a protocol-based ultrasound-guided salvage brachytherapy as re-irradiation for local recurrent prostate cancer.
Schönle N; Strnad V; Lotter M; Kreppner S; Fietkau R
Radiother Oncol; 2020 Sep; 150():201-205. PubMed ID: 32593646
[TBL] [Abstract][Full Text] [Related]
17. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated helical tomotherapy (75 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term analysis of gastrointestinal and genitourinary toxicity.
Kong M; Hong SE; Chang SG
Onco Targets Ther; 2014; 7():553-66. PubMed ID: 24748805
[TBL] [Abstract][Full Text] [Related]
19. Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy.
Rutenberg MS; Meister M; Amin PP; Hussain A; Naslund MJ; Kwok Y
Brachytherapy; 2016; 15(6):722-729. PubMed ID: 27693225
[TBL] [Abstract][Full Text] [Related]
20. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]